How much of GE HealthCare's original April 2025 buyback authorization has been used?

The company spent $200 million on buybacks in Q2 2026 with $500 million remaining under the April 2025 authorization. This implies the original authorization was at least $700 million, though the full authorized amount is not disclosed in this earnings release.

What was the average price paid for shares in Q2 2026?

GE HealthCare repurchased 3.3 million shares for $200 million, resulting in an average price of approximately $60.61 per share during the quarter.

Does the filing disclose the execution method used for these buybacks?

No, the earnings release does not specify whether the repurchases were executed under Rule 10b-18 open-market purchases, a 10b5-1 plan, or another mechanism. The company provides only the total shares and dollar amount repurchased.

How do these Q2 buybacks compare to prior periods?

For the six months ended June 30, 2026, the company repurchased shares for $300 million ($100 million in Q1 2026 plus $200 million in Q2 2026), compared to $100 million in the first half of 2025, indicating an acceleration in the pace of repurchases.

Is GE HealthCare prioritizing buybacks given its capital allocation strategy?

Buybacks appear to be a moderate capital deployment priority alongside dividends ($32 million paid in H1 2026) and strategic acquisitions ($2.3 billion in H1 2026). The remaining $500 million authorization suggests measured, opportunistic execution rather than aggressive shareholder return targets.

GEHC 8-K Filed 2026-07-29 Execution disclosure

GE HealthCare repurchased 3.3M shares for $200M in Q2 2026

Company executed buybacks under April 2025 authorization with $500M remaining in program

Shares repurchased3.3M

Avg price paid$60.61

Remaining$500M

MechanismNot specified

What the filing says

GE HealthCare Technologies repurchased 3.3 million shares for a total consideration of $200 million during the second quarter of 2026, bringing the average price paid to approximately $60.61 per share. The repurchases were executed under a share repurchase program authorized by the Board of Directors in April 2025.

As of the second quarter close on June 30, 2026, the company had $500 million remaining in authorized buyback capacity under the April 2025 program. The company did not disclose the specific execution mechanism for these repurchases in this earnings release.

The buyback was disclosed as part of GE HealthCare's capital deployment summary for Q2 2026, alongside cash flow generation of $168 million from operating activities and free cash flow of $68 million. The company also declared a quarterly dividend of $0.035 per share.

null

The Company repurchased 3.3 million shares for total consideration of $200 million; $500 million remaining in the share repurchase program authorized by the Board of Directors in April 2025. — GE HealthCare Technologies Inc. 8-K filing · View on SEC EDGAR →

What this means

GE HealthCare executed modest share repurchases in Q2 2026 totaling $200 million, reducing dilution and returning capital to remaining shareholders. With 3.3 million shares retired against a diluted share count of approximately 454 million, the buyback's EPS accretion impact is modest but measurable. The $500 million remaining authorization provides flexibility for future repurchases, though the company is also investing heavily in acquisitions (notably $2.3 billion in business purchases in H1 2026) and managing elevated debt levels of $10.1 billion, constraining capital allocation options.

Frequently asked questions

How much of GE HealthCare's original April 2025 buyback authorization has been used?: The company spent $200 million on buybacks in Q2 2026 with $500 million remaining under the April 2025 authorization. This implies the original authorization was at least $700 million, though the full authorized amount is not disclosed in this earnings release.
What was the average price paid for shares in Q2 2026?: GE HealthCare repurchased 3.3 million shares for $200 million, resulting in an average price of approximately $60.61 per share during the quarter.
Does the filing disclose the execution method used for these buybacks?: No, the earnings release does not specify whether the repurchases were executed under Rule 10b-18 open-market purchases, a 10b5-1 plan, or another mechanism. The company provides only the total shares and dollar amount repurchased.
How do these Q2 buybacks compare to prior periods?: For the six months ended June 30, 2026, the company repurchased shares for $300 million ($100 million in Q1 2026 plus $200 million in Q2 2026), compared to $100 million in the first half of 2025, indicating an acceleration in the pace of repurchases.
Is GE HealthCare prioritizing buybacks given its capital allocation strategy?: Buybacks appear to be a moderate capital deployment priority alongside dividends ($32 million paid in H1 2026) and strategic acquisitions ($2.3 billion in H1 2026). The remaining $500 million authorization suggests measured, opportunistic execution rather than aggressive shareholder return targets.

execution healthcare Q2-2026 mid-cap rule-10b-18-implied

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.